Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.81 |
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | TERT | O14746 | 3/20 | 0.70 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21440072 | 1.00 | MAOB (0.81) | MAOBMAOANPC1RAB9AMEN1 | |
| SCHEMBL3318038 | 0.93 | EGFR (0.76) | MAOBMAOANPC1RAB9AMEN1 | |
| SCHEMBL3308921 | 0.92 | MAOB (0.83) | MAOBMAOAKMT2APTGS2CA1 | |
| SCHEMBL23052167 | 0.89 | NPC1 (0.71) | MAOBMAOANPC1RAB9AMEN1 | |
| SCHEMBL23052465 | 0.89 | NPC1 (0.71) | MAOBMAOANPC1RAB9AMEN1 | |
| SCHEMBL16181219 | 0.87 | MAOB (0.74) | MAOBMAOAKMT2AEGFRPTGS2 | |
| SCHEMBL27790823 | 0.85 | MAOA (1.00) | MAOBMAOANPC1RAB9AMEN1 | |
| SCHEMBL14133888 | 0.84 | MAOB (0.71) | MAOBKMT2APTGS2CA1CA2 | |
| SCHEMBL23052467 | 0.84 | MAOB (0.71) | MAOBMAOAKMT2APTGS2CA1 | |
| SCHEMBL3314904 | 0.83 | ACHE (0.71) | MAOBMAOAKMT2AEGFRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307381-B1 | NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-2687513-B1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| EP-2687513-A1 | Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases | Ludwig-Maximilians-Universität München (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, APP, HYPK | MAOB 741/4885MAOA 744/4885NPC1 363/4885 |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, HYPK, IK | MAOB 696/4885MAOA 987/4885NPC1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.